Literature DB >> 21587271

Five-year visual outcome following laser photocoagulation of diabetic macular oedema.

S Jyothi1, S Sivaprasad.   

Abstract

OBJECTIVE: To evaluate the 5-year visual outcome associated with laser photocoagulation treatment of diabetic macular oedema (DMO), and to investigate the relationship between systemic factors and visual outcomes in a real-life setting.
METHODS: The mean annual visual outcomes and systemic parameters of 100 consecutive subjects with type 2 diabetes who underwent the first session of focal/grid macular laser photocoagulation for clinically significant macular oedema between 2003 and 2004 were collected retrospectively and compared with the outcomes of the laser arm of the Diabetic Retinopathy Clinical Research Network (DRCRN trial comparing intravitreal triamcinolone acetonide injection with laser photocoagulation treatment for DMO). The primary outcome measures included the mean change in visual acuity (VA) in 5 years and the influence of systemic factors on final visual outcome.
RESULTS: The mean change in VA at 5 years was -5.23 in a real-life setting for an inner city population. The 3-year outcome was inferior to the clinical trial results with more people gaining vision (≥15 letter gain) in the DRCRN group compared with this cohort (26 vs 9%). Furthermore, three times more patients lost vision (>15 letter loss) in the real-life setting of this cohort compared with the clinical trial results of the DRCRN group (27 vs 8%, respectively).
CONCLUSIONS: The visual outcomes and the control of systemic factors of patients with DMO in this cohort were inferior to those recruited for the clinical trial involving the DRCRN group.

Entities:  

Mesh:

Year:  2011        PMID: 21587271      PMCID: PMC3178156          DOI: 10.1038/eye.2011.102

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  23 in total

1.  Socio-economic and ethnic inequalities in diabetes retinal screening.

Authors:  M C Gulliford; H Dodhia; M Chamley; K McCormick; M Mohamed; S Naithani; S Sivaprasad
Journal:  Diabet Med       Date:  2010-03       Impact factor: 4.359

2.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2010-04-28       Impact factor: 12.079

3.  Evaluation of the role of vascular endothelial growth factor in diabetic retinopathy.

Authors:  Reda A Mahdy; Waled M Nada
Journal:  Ophthalmic Res       Date:  2010-08-19       Impact factor: 2.892

4.  Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema.

Authors:  Lloyd Paul Aiello; Allison R Edwards; Roy W Beck; Neil M Bressler; Matthew D Davis; Frederick Ferris; Adam R Glassman; Michael S Ip; Kellee M Miller
Journal:  Ophthalmology       Date:  2010-02-01       Impact factor: 12.079

5.  The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group.

Authors: 
Journal:  Diabetes       Date:  1986-05       Impact factor: 9.461

6.  Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.

Authors:  Neil M Bressler; Allison R Edwards; Roy W Beck; Christina J Flaxel; Adam R Glassman; Michael S Ip; Craig Kollman; Baruch D Kuppermann; Thomas W Stone
Journal:  Arch Ophthalmol       Date:  2009-12

7.  The prevalence of diabetic retinopathy among adults in the United States.

Authors:  John H Kempen; Benita J O'Colmain; M Cristina Leske; Steven M Haffner; Ronald Klein; Scot E Moss; Hugh R Taylor; Richard F Hamman
Journal:  Arch Ophthalmol       Date:  2004-04

8.  Family practices' achievement of diabetes quality of care targets and risk of screen-detected diabetic retinopathy.

Authors:  Martin C Gulliford; Hiten Dodhia; Sobha Sivaprasad; Mark Ashworth
Journal:  PLoS One       Date:  2010-04-29       Impact factor: 3.240

9.  Diabetic retinopathy: contemporary prevalence in a well-controlled population.

Authors:  Jonathan Betz Brown; Kathryn L Pedula; Kent H Summers
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

10.  The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

View more
  5 in total

1.  Importance of 3-D image reconstruction of spectral-domain OCT on outcome of grid laser photocoagulation for diffuse diabetic macular edema.

Authors:  Avinoam Ophir; Rana Hanna; Michael R Martinez
Journal:  Int J Ophthalmol       Date:  2013-12-18       Impact factor: 1.779

2.  Intravitreal bevacizumab injections for diabetic macular edema - predictors of response: a retrospective study.

Authors:  Lavnish Joshi; Asaf Bar; Oren Tomkins-Netzer; Satish Yaganti; Jiten Morarji; Panayiotis Vouzounis; Sophie Seguin-Greenstein; Simon R Taylor; Sue Lightman
Journal:  Clin Ophthalmol       Date:  2016-10-21

Review 3.  Diabetic Macular Edema: From Old Concepts to New Therapeutic Avenues.

Authors:  Ahmad M Mansour; Jose S Pulido; J Fernando Arevalo
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2015

Review 4.  Real-World Efficacy and Safety of Fluocinolone Acetonide Implant for Diabetic Macular Edema: A Systematic Review.

Authors:  Laurent Kodjikian; Stephanie Baillif; Catherine Creuzot-Garcher; Marie-Noëlle Delyfer; Frédéric Matonti; Michel Weber; Thibaud Mathis
Journal:  Pharmaceutics       Date:  2021-01-07       Impact factor: 6.321

5.  Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2(Akita) diabetic mouse.

Authors:  Jose R Hombrebueno; Imran H A Ali; Heping Xu; Mei Chen
Journal:  Sci Rep       Date:  2015-12-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.